NewLink Genetics (NLNK) Strengthens Patent on Cancer Therapy D-1MT
Tweet
Share
E-mailGet Alerts NLNK Hot Sheet
Join SI Premium – FREE
NewLink Genetics (Nasdaq: NLNK) received a 'notice of allowance' from USPTO regarding its patent on cancer therapy D-1MT, allowing it broader rights to protection.
"These patents will strengthen our D-1MT franchise in the United States," commented Dr. Charles Link, NewLink's Chairman and CEO, "and should facilitate our ongoing discussions with potential development and marketing partners for this product candidate."
IDO pathway inhibitors, including D-1MT, represent a potential breakthrough approach to cancer therapy using small-molecule, anti-toleragenic product candidates intended to counteract a key mechanism by which tumors evade immune-mediated destruction.
Get Alerted Instantly When News Breaks on NLNK and Other Stocks with EasyStockAlerts.com
"These patents will strengthen our D-1MT franchise in the United States," commented Dr. Charles Link, NewLink's Chairman and CEO, "and should facilitate our ongoing discussions with potential development and marketing partners for this product candidate."
IDO pathway inhibitors, including D-1MT, represent a potential breakthrough approach to cancer therapy using small-molecule, anti-toleragenic product candidates intended to counteract a key mechanism by which tumors evade immune-mediated destruction.
Get Alerted Instantly When News Breaks on NLNK and Other Stocks with EasyStockAlerts.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Veg House Holdings (VEG) Announces 1M Share IPO at $5/sh
- Michelin misses Q1 sales estimates amid weaker volumes
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
